StageZero Life Sciences (TSXV:SZLS.H) Earnings Power Value (EPV): C$-3.12 (As of Sep24)


TSXV:SZLS.H StageZero Life Sciences Ltd TSXV:SZLS.H
10 GF Score
Price C$0.04
View Full Analysis

What is StageZero Life Sciences Earnings Power Value (EPV)?

StageZero Life Sciences TSXV:SZLS.H 10 Earnings Power Value (EPV) is C$-3.12 as of Sep24. GuruFocus rates TSXV:SZLS.H with a GF Score™ of 10/100.

As of Sep24, StageZero Life Sciences's earnings power value is C$-3.12. *

* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.

Margin of Safety is N/A.

The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future. Assumption: Current profitability is sustainable.


StageZero Life Sciences  (TSXV:SZLS.H) Earnings Power Value (EPV) Explanation

Assumption: Current profitability is sustainable.

Earnings power value (EPV) uses a very basic equation which assumes no growth, although it does rely on an assumption about the cost of capital as well as the fact that current earnings are sustainable. It also involves several adjustments to clean up the underlying Earnings figures.


Be Aware

Though using today's earnings in calculating Earnings Power Value, GuruFocus is normalizing these earnings to the business cycle. This eliminates the effects on profitability of valuing the firm at different points in the business cycle. This means that we are considering the average earnings over 5 years.


StageZero Life Sciences Earnings Power Value (EPV) Related Terms


StageZero Life Sciences Earnings Power Value (EPV) Historical Data

* Premium members only.

The historical data trend for StageZero Life Sciences's Earnings Power Value (EPV) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

StageZero Life Sciences Earnings Power Value (EPV) Chart

StageZero Life Sciences Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Earnings Power Value (EPV)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -17.94 -7.89 -11.61 -12.08 -13.80

StageZero Life Sciences Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Mar24 Jun24 Sep24
Earnings Power Value (EPV) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.36 -5.42 -5.22 -5.03 -3.12

TSXV:SZLS.H vs IDTA, TTOO, NSTM: Earnings Power Value (EPV) Comparison

For the Diagnostics & Research subindustry, StageZero Life Sciences's Earnings Power Value (EPV), along with its competitors' market caps and Earnings Power Value (EPV) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


StageZero Life Sciences Earnings Power Value (EPV) vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, StageZero Life Sciences's Earnings Power Value (EPV) distribution charts can be found below:

* The bar in red indicates where StageZero Life Sciences's Earnings Power Value (EPV) falls into.


TSXV:SZLS.H
10GF Score
StageZero Life Sciences Ltd TSXV:SZLS.H
Earnings Power Value (EPV) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

StageZero Life Sciences Earnings Power Value (EPV) Calculation

Earnings Power Value also known as just Earnings Power is a valuation technique popularised by Bruce Greenwald, an authority on value investing at Columbia University. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future.

The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. This valuation tool excludes the potential growth that a company may have so that needs to be looked at separately. Since future growth is excluded from the analysis, only the maintenance capital expenditures are subtracted from after-tax EBIT (earnings before interest and taxes) and growth capex is ignored.

StageZero Life Sciences's "Earning Power" Calculation:

Average of Last 20 Quarters Last Quarter
Revenue 4.37
DDA 0.42
Operating Margin % -820.48
SGA * 25% 1.68
Tax Rate % 0.00
Maintenance Capex 0.27
Cash and Cash Equivalents 0.02
Short-Term Debt 1.53
Long-Term Debt 1.36
Shares Outstanding (Diluted) 123.53

1. Start with "Earnings" not including accounting adjustments (one-time charges not excluded unless policy has changed). "Earnings" are "Operating Income.

2. Look at average margins over a business/Industry cycle: Average Operating Margin = -820.48%

To normalize margins and eliminate the effects on profitability of valuing the firm at different points in the business cycle, it is usually best to take a long-term average of operating margins. Ideally this would be as long as 10 years and include at least one economic downturn. However, since most of companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year margin.

3. Multiply average margins by sustainable revenues and then adjust for maintenance SGA. This yields "normalized" EBIT:

To be conservative, GuruFocus uses an average of the 5 year revenues as the sustainable revenue.
EPV analysis recognises that part of SG&A expenditure is made to maintain and replace the existing assets, while part is made to grow sales. Since EPV is only interested in what it costs a going concern to maintain its existing asset base, it adds back a percentage of SG&A (between 15% and 50% - this is a matter of judgment and industry knowledge) to make up for the fact that some of this expenditure went to fund growth and shouldn't be accounted for. To start off, we assume 25% for the sake of prudence.
Sustainable Revenue = C$4.37 Mil, Average Operating Margin = -820.48%, Average Adjusted SGA = 1.68,
therefore "Normalized" EBIT = Sustainable Revenue * Average Operating Margin + Average Adjusted SGA = 4.37 * -820.48% +1.68 = C$-34.18856374 Mil.

4. Multiply by one minus Average Tax Rate (NOPAT):

Same as average operating margin calculation, GuruFocus takes an average of the 5 years tax rates.
Average Tax Rate = 0.00%, and "Normalized" EBIT = C$-34.18856374 Mil,
therefore After-tax "Normalized" EBIT = "Normalized" EBIT * ( 1 - Average Tax Rate ) = -34.18856374 * ( 1 - 0.00% ) = C$-34.18856374 Mil.

5. Add back Excess Depreciation (after tax at 1/2 average tax rate). This yields "normalized" Earnings:

Excess Depreciation = Average DDA * % of Excess Depreciation (after tax at 1/2 average tax rate) = 0.42 * 0.5 * 0.00% = C$0 Mil.
"Normalized" Earnings = After-tax "Normalized" EBIT + Excess Depreciation = -34.18856374 + 0 = C$-34.18856374 Mil.

6. Adjusted for Maintenance Capital Expenditure:

First, calculate the revenue change regarding to the previous year. If the revenue decreased from the previous year, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous year, then calculate the percentage of Net PPE as of corresponding Revenue.
Third, calculate Capital Expenditure (positive) - percentage of Net PPE as of corresponding Revenue * revenue increase.
If [Capital Expenditure (positive) - percentage of Net PPE as of corresponding Revenue * revenue increase] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - percentage of Net PPE as of corresponding Revenue * revenue increase] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - percentage of Net PPE as of corresponding Revenue * revenue increase.
Fourth, GuruFocus uses an average of the 5 year maintenance capital expenditures as maintenance CAPEX.
StageZero Life Sciences's Average Maintenance CAPEX = C$0.27 Mil *.
* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.

7. Investors require a return of "WACC" for the risk they are taking: WACC = 9%

8. StageZero Life Sciences's current cash and cash equivalent = C$0.02 Mil.
StageZero Life Sciences's current interest bearing debt = Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation = 1.36 + 1.53 = C$2.889 Mil.
StageZero Life Sciences's current Shares Outstanding (Diluted Average) = 123.53 Mil.

StageZero Life Sciences's Earnings Power Value (EPV) for Sep24 is calculated as:

EPV = ( ( Norm. Earnings-Maint. CAPEX *) / WACC + CashandEquiv - Int. Bearing Debt ) / Shares Outstanding (Diluted Average)
= ( ( -34.18856374 - 0.27)/ 9%+0.02-2.889 )/123.53
=-3.12

Margin of Safety (EPV)=( Earnings Power Value (EPV)-Current Price )/Earnings Power Value (EPV)
=( -3.1225820666902-0.04 )/-3.1225820666902
= N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.

What does a Earnings Power Value (EPV) of C$-3.12 mean?
StageZero Life Sciences (TSXV:SZLS.H) has a Earnings Power Value (EPV) of C$-3.12 as of Sep24. Bruce Greenwald's earnings power value focuses on current earnings without factoring in future growth. View historical data on StageZero Life Sciences and its competitors.
Is StageZero Life Sciences' Earnings Power Value (EPV) too high?
StageZero Life Sciences' current Earnings Power Value (EPV) is C$-3.12. Overall, StageZero Life Sciences has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does StageZero Life Sciences' Earnings Power Value (EPV) compare to IDTA and TTOO?
StageZero Life Sciences' Earnings Power Value (EPV) of C$-3.12 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Power Value (EPV) for a Medical Diagnostics & Research company?
A good Earnings Power Value (EPV) depends on the Medical Diagnostics & Research industry context. However, Earnings Power Value (EPV) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Power Value (EPV) mean?
A high Earnings Power Value (EPV) can signal that a stock is expensive relative to its fundamentals. Bruce Greenwald's earnings power value focuses on current earnings without factoring in future growth. View historical data on StageZero Life Sciences and its competitors. StageZero Life Sciences's current Earnings Power Value (EPV) is C$-3.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is StageZero Life Sciences stock overvalued right now?
StageZero Life Sciences (TSXV:SZLS.H) has a current Earnings Power Value (EPV) of C$-3.12. The current Earnings Power Value (EPV) is C$-3.12. StageZero Life Sciences' overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Power Value (EPV) calculated?
Earnings Power Value (EPV) is calculated from a company's financial statements. For StageZero Life Sciences (TSXV:SZLS.H), the current Earnings Power Value (EPV) is C$-3.12 as of Sep24. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

StageZero Life Sciences Business Description

Address 70 East Beaver Creek Road, Unit 30, Richmond Hill, ON, CAN, L4B 3B2
StageZero Life Sciences Ltd is a vertically integrated healthcare company at the nexus of three sectors of healthcare; Early Cancer Detection, Liquid Biopsy, and Global Telehealth. It is focused on minimizing the risk of cancer and other chronic diseases through early detection and intervention. It continues to develop and commercialize proprietary molecular diagnostic tests for the early detection of diseases and personalized health management, with a focus on cancer-related indications. It has developed a proprietary platform technology, the Sentinel Principle, to identify novel biomarkers from whole blood. The Company's lead product, Aristotle, is a blood-based molecular diagnostic assessment that can detect an individual's current risk for potentially having a variety of cancers.
10GF Score

Get the complete analysis for TSXV:SZLS.H

Earnings Power Value (EPV) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$0.04
Price